Heyman Richard A. sold $41K of ORIC (indirect holdings)

Heyman Richard A. sold 3,200 indirectly-held shares of Oric Pharmaceuticals, Inc. (ORIC) at $12.91 on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Heyman Richard A.
Published Oct 2, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ORIC
Bearish
medium confidence
Mentioned
$ORIC
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORICBearishLow
01

Why it matters

The transaction is small and pre‑arranged, suggesting limited new information for traders.

02

Market read

A routine insider sale with modest size; unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data releases could outweigh the modest insider sell.

Relevance 2/10Novelty 2/10Timing: post‑market on 2026‑10‑01

Background

Form 4 filings disclose insider transactions; this filing reports a director's sale under a 10b5‑1 plan.

Company-level read

Ticker impact

$ORICBearishMedium confidence
Context

Director Richard Heyman sold 3,200 shares for $41,325 via a 10b5-1 plan, reducing his stake.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

The sale is small ($41k) and executed under a pre‑arranged plan, limiting informational value but may cause minor short‑term downside.

Market effects

Minimal impact on the biotech sector; typical insider sales are routine.

No broader regional effect.

Limited to ORIC shareholders.

Counterpoint

The sale could be purely liquidity‑driven and not indicative of company fundamentals.

Key entities

  • Oric Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ under ticker ORIC.

  • Richard A. Heyman

    Director of Oric Pharmaceuticals.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo